Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Resverlogix Corp T.RVX

Alternate Symbol(s):  RVXCF

Resverlogix Corp. is a Canada-based late-stage biotechnology company. The Company is engaged in epigenetics, with a focus on developing therapies for the benefit of patients with chronic diseases. Its epigenetic therapies are designed to regulate the expression of disease-causing genes. The Company's clinical program is focused on evaluating its lead candidate apabetalone (RVX-208) for the treatment of cardiovascular disease and associated comorbidities, and post-COVID-19 conditions. RVX-208 is a small molecule that is a selective bromodomain and extra-terminal (BET) inhibitor. BET bromodomain inhibition is an epigenetic mechanism that can regulate disease-causing genes. RVX-208 is a BET inhibitor selective for the second bromodomain (BD2) within the BET proteins. It partners with EVERSANA, to support the commercialization of RVX-208 for cardiovascular disease, post-COVID-19 conditions, and pulmonary arterial hypertension in Canada and the United States.


TSX:RVX - Post by User

Comment by narmacon Jan 22, 2022 7:54am
229 Views
Post# 34346236

RE:RE:Canadian Covid pill potential Edmonton Journal Jan 18, 2022

RE:RE:Canadian Covid pill potential Edmonton Journal Jan 18, 2022 QT,,,,,,you cant be serious,,,,,,why would any shareholder take DMcC at his word,,,,,,good grief,,this man has absolutley no idea around research protocol or what takes place during a trial or for that matter what reason or when it does!!!,,,,listening to his gobblygook is the definition of insanity!!!,,now our future seems really to be decided by accident and ad hoc, supported by complacency of our large inside shareholders. Perhaps when ROI starts to bite into HL,ORI etc. and others big time they actually take control and restructure this company. If we miss stellar data from these C19 trials we are dead money for years out!!!
<< Previous
Bullboard Posts
Next >>